Determining the Optimal Examined Lymph Node for Accurate Staging and Long-term Survival in Rectal Cancer
1 other identifier
observational
7,694
0 countries
N/A
Brief Summary
A multi-institutional registry of collected data on patients with rectal cancer who underwent surgical resection between January 2009 and December 2018 at the departments of colorectal surgery of five medical institutions in China
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2009
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedFirst Submitted
Initial submission to the registry
October 4, 2022
CompletedFirst Posted
Study publicly available on registry
October 7, 2022
CompletedOctober 7, 2022
October 1, 2022
9.9 years
October 4, 2022
October 6, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
lymph node number
lymph nodes were harvested during surgical resection of rectal cancer
during the surgery
Interventions
Lymph nodes were harvested during surgical resection of rectal cancer
Eligibility Criteria
Information about patients (age, sex and year of diagnosis), tumor (TNM stages, histology, size and differentiation), treatments (resection type, chemotherapy), and outcome variables (follow-up time and survival status) were obtained in SEER database and China registry
You may qualify if:
- Rectal cancer patients in stage I-III who underwent surgical resection for first primary rectal cancer with at least one lymph node were eligible
You may not qualify if:
- Patients with missing values on lymph node count and clinical features were excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Del Paggio JC, Peng Y, Wei X, Nanji S, MacDonald PH, Krishnan Nair C, Booth CM. Population-based study to re-evaluate optimal lymph node yield in colonic cancer. Br J Surg. 2017 Jul;104(8):1087-1096. doi: 10.1002/bjs.10540. Epub 2017 May 24.
PMID: 28542954BACKGROUNDGuan X, Jiao S, Wen R, Yu G, Liu J, Miao D, Wei R, Zhang W, Hao L, Zhou L, Lou Z, Liu S, Zhao E, Wang G, Zhang W, Wang X. Optimal examined lymph node number for accurate staging and long-term survival in rectal cancer: a population-based study. Int J Surg. 2023 Aug 1;109(8):2241-2248. doi: 10.1097/JS9.0000000000000320.
PMID: 37428195DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 4, 2022
First Posted
October 7, 2022
Study Start
January 1, 2009
Primary Completion
December 10, 2018
Study Completion
December 31, 2018
Last Updated
October 7, 2022
Record last verified: 2022-10